| scholarly article | Q13442814 |
| P50 | author | David Vaudry | Q38544625 |
| Nicole Gallo-Payet | Q47451650 | ||
| P2093 | author name string | Alain Fournier | |
| Hubert Vaudry | |||
| Dorthe Cartier | |||
| Isabelle Lihrmann | |||
| Pierre Freger | |||
| Magali Basille | |||
| Bruno Gonzalez | |||
| P2860 | cites work | Structure, expression, and chromosomal localization of the type I human vasoactive intestinal peptide receptor gene | Q24564119 |
| Single-Step Method of RNA Isolation by Acid Guanidinium Thiocyanate–Phenol–Chloroform Extraction | Q25938986 | ||
| Cloning and functional characterization of the human vasoactive intestinal peptide (VIP)-2 receptor | Q28300634 | ||
| Pituitary adenylate cyclase-activating polypeptide and sonic hedgehog interact to control cerebellar granule precursor cell proliferation | Q28507296 | ||
| Expression of PACAP, and PACAP type 1 (PAC1) receptor mRNA during development of the mouse embryo | Q28509469 | ||
| Differential signal transduction by five splice variants of the PACAP receptor | Q28566746 | ||
| PACAP is an anti-mitogenic signal in developing cerebral cortex. | Q31929784 | ||
| Pituitary adenylate cyclase-activating polypeptide prevents the effects of ceramides on migration, neurite outgrowth, and cytoskeleton remodeling | Q33850713 | ||
| Pituitary adenylate cyclase-activating polypeptide protects rat cerebellar granule neurons against ethanol-induced apoptotic cell death | Q34029443 | ||
| Biochemical and therapeutic effects of antioxidants in the treatment of Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis | Q34200376 | ||
| Pituitary adenylate cyclase-activating polypeptide and its receptors in amphibians. | Q34310714 | ||
| Cloning and characterization of the signal transduction of four splice variants of the human pituitary adenylate cyclase activating polypeptide receptor. Evidence for dual coupling to adenylate cyclase and phospholipase C. | Q34384700 | ||
| Neurotrophic activity of pituitary adenylate cyclase-activating polypeptide on rat cerebellar cortex during development | Q35606272 | ||
| The neuroprotective effect of pituitary adenylate cyclase-activating polypeptide on cerebellar granule cells is mediated through inhibition of the CED3-related cysteine protease caspase-3/CPP32 | Q37296125 | ||
| Investigation and characterization of receptors for pituitary adenylate cyclase-activating polypeptide in human brain by radioligand binding and chemical cross-linking | Q42464380 | ||
| PACAP protects cerebellar granule neurons against oxidative stress-induced apoptosis | Q44004718 | ||
| Pituitary adenylate cyclase‐activating polypeptide prevents C2‐ceramide‐induced apoptosis of cerebellar granule cells | Q44401713 | ||
| VIP and PACAP induce selective neuronal differentiation of mouse embryonic stem cells. | Q44791890 | ||
| Investigation of the interaction of VIP binding sites with VIP and PACAP in human brain | Q44828984 | ||
| PACAP inhibits delayed rectifier potassium current via a cAMP/PKA transduction pathway: evidence for the involvement of I k in the anti-apoptotic action of PACAP. | Q44831617 | ||
| Opposite regulation of the mitochondrial apoptotic pathway by C2-ceramide and PACAP through a MAP-kinase-dependent mechanism in cerebellar granule cells | Q45166159 | ||
| Characterization and localization of pituitary adenylate cyclase-activating polypeptide (PACAP) binding sites in the brain of the frog Rana ridibunda | Q48140323 | ||
| Regulators of cerebellar granule cell development act through specific signaling pathways | Q48287966 | ||
| Expression of pituitary adenylate cyclase activating polypeptide (PACAP) in the postnatal and adult rat cerebellar cortex | Q48403529 | ||
| Pituitary adenylate cyclase-activating polypeptide stimulates both c-fos gene expression and cell survival in rat cerebellar granule neurons through activation of the protein kinase A pathway | Q48473899 | ||
| Binding sites for pituitary adenylate cyclase activating polypeptide (PACAP): comparison with vasoactive intestinal polypeptide (VIP) binding site localization in rat brain sections | Q48508938 | ||
| Primary structure of frog pituitary adenylate cyclase-activating polypeptide (PACAP) and effects of ovine PACAP on frog pituitary | Q48620158 | ||
| Pituitary adenylate cyclase-activating polypeptide promotes cell survival and neurite outgrowth in rat cerebellar neuroblasts | Q48720827 | ||
| Prevention of ischemia-induced death of hippocampal neurons by pituitary adenylate cyclase activating polypeptide | Q48890841 | ||
| Isolation of a neuropeptide corresponding to the N-terminal 27 residues of the pituitary adenylate cyclase activating polypeptide with 38 residues (PACAP38). | Q48931112 | ||
| VIP and PACAP 38 modulate ibotenate-induced neuronal heterotopias in the newborn hamster neocortex | Q49115803 | ||
| Isolation of a novel 38 residue-hypothalamic polypeptide which stimulates adenylate cyclase in pituitary cells | Q69772725 | ||
| Concentrations of pituitary adenylate cyclase activating polypeptide (PACAP) in human brain nuclei | Q71046285 | ||
| Localization and characterization of PACAP receptors in the rat cerebellum during development: evidence for a stimulatory effect of PACAP on immature cerebellar granule cells | Q72259525 | ||
| Ontogeny of pituitary adenylate cyclase-activating polypeptide (PACAP) receptors in the rat cerebellum: a quantitative autoradiographic study | Q72503954 | ||
| Quantitative autoradiographic study of somatostatin receptors in the adult human cerebellum | Q72520276 | ||
| Delayed systemic administration of PACAP38 is neuroprotective in transient middle cerebral artery occlusion in the rat | Q73843824 | ||
| Comparative distribution of pituitary adenylate cyclase-activating polypeptide (PACAP) binding sites and PACAP receptor mRNAs in the rat brain during development | Q74280099 | ||
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | cerebellum | Q130983 |
| P304 | page(s) | 468-78 | |
| P577 | publication date | 2006-06-01 | |
| P1433 | published in | The Journal of Comparative Neurology | Q3186907 |
| P1476 | title | Localization and characterization of pituitary adenylate cyclase-activating polypeptide receptors in the human cerebellum during development | |
| P478 | volume | 496 |
| Q34460069 | Cellular commitment in the developing cerebellum |
| Q35948321 | Cerebellar cortical-layer-specific control of neuronal migration by pituitary adenylate cyclase-activating polypeptide. |
| Q46496697 | Changes in the expression of PACAP-like compounds during the embryonic development of the earthworm Eisenia fetida. |
| Q54941426 | Discovery of PACAP and its receptors in the brain. |
| Q38069825 | How does angiotensin AT(2) receptor activation help neuronal differentiation and improve neuronal pathological situations? |
| Q37158885 | Interaction of PACAP with Sonic hedgehog reveals complex regulation of the hedgehog pathway by PKA. |
| Q37198666 | Interactions of PACAP and ceramides in the control of granule cell apoptosis during cerebellar development |
| Q48090932 | Molecular, cellular, and functional characterizations of pituitary adenylate cyclase-activating polypeptide and its receptors in the cerebellum of New and Old World monkeys |
| Q33806745 | PAC1 receptor (ADCYAP1R1) genotype and problematic alcohol use in a sample of young women |
| Q42502409 | PACAP and C2-ceramide generate different AP-1 complexes through a MAP-kinase-dependent pathway: involvement of c-Fos in PACAP-induced Bcl-2 expression |
| Q39016755 | PACAP enhances barrier properties of cerebral microvessels |
| Q33936997 | Proteomics of rat hypothalamus, hippocampus and pre-frontal/frontal cortex after central administration of the neuropeptide PACAP. |
| Q37528174 | Role of PACAP in controlling granule cell migration |
| Q36787413 | The neuropeptide pituitary adenylate cyclase-activating polypeptide exerts anti-apoptotic and differentiating effects during neurogenesis: focus on cerebellar granule neurones and embryonic stem cells. |
| Q41879295 | VPAC2 receptor agonist BAY 55-9837 increases SMN protein levels and moderates disease phenotype in severe spinal muscular atrophy mouse models |
| Q45919358 | Vasoactive intestinal polypeptide immunoreactivity in the human cerebellum: qualitative and quantitative analyses. |
Search more.